LEADER 04153nam 2200709Ia 450 001 9910459384503321 005 20200520144314.0 010 $a1-282-63948-X 010 $a9786612639487 010 $a1-4008-3511-9 024 7 $a10.1515/9781400835119 035 $a(CKB)2670000000035226 035 $a(EBL)540270 035 $a(OCoLC)655342133 035 $a(SSID)ssj0000427070 035 $a(PQKBManifestationID)11965268 035 $a(PQKBTitleCode)TC0000427070 035 $a(PQKBWorkID)10390665 035 $a(PQKB)10069665 035 $a(MiAaPQ)EBC540270 035 $a(MdBmJHUP)muse36704 035 $a(DE-B1597)446670 035 $a(OCoLC)979745514 035 $a(DE-B1597)9781400835119 035 $a(Au-PeEL)EBL540270 035 $a(CaPaEBR)ebr10394772 035 $a(CaONFJC)MIL263948 035 $a(EXLCZ)992670000000035226 100 $a20091106d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aReputation and power organizational image and pharmaceutical regulation at the FDA$b[electronic resource] /$fDaniel Carpenter 205 $aCourse Book 210 $aPrinceton $cPrinceton University Press$dc2010 215 $a1 online resource (825 p.) 225 1 $aPrinceton studies in American politics 300 $aDescription based upon print version of record. 311 $a0-691-14179-7 311 $a0-691-14180-0 320 $aIncludes bibliographical references and index. 327 $aCover; CONTENTS; LIST OF ILLUSTRATIONS; LIST OF TABLES; ACKNOWLEDGMENTS; LIST OF ABBREVIATIONS AND ACRONYMS; INTRODUCTION: The Gatekeeper; CHAPTER ONE: Reputation and Regulatory Power; PART ONE: ORGANIZATIONAL EMPOWERMENT AND CHALLENGE; CHAPTER TWO: Reputation and Gatekeeping Authority: The Federal Food, Drug and Cosmetic Act of 1938 and Its Aftermath; CHAPTER THREE: The Ambiguous Emergence of American Pharmaceutical Regulation, 1944-1961; CHAPTER FOUR: Reputation and Power Crystallized: Thalidomide, Frances Kelsey, and Phased Experiment, 1961-1966 327 $aCHAPTER FIVE: Reputation and Power Institutionalized: Scientific Networks, Congressional Hearings, and Judicial Affirmation, 1963-1986CHAPTER SIX: Reputation and Power Contested: Emboldened Audiences in Cancer and AIDS, 1977-1992; PART TWO: PHARMACEUTICAL REGULATION AND ITS AUDIENCES; CHAPTER SEVEN: Reputation and the Organizational Politics of New Drug Review; CHAPTER EIGHT: The Governance of Research and Development: Gatekeeping Power, Conceptual Guidance, and Regulation by Satellite; CHAPTER NINE: The Other Side of the Gate: Reputation, Power, and Post-Market Regulation 327 $aCHAPTER TEN: The De?tente of Firm and RegulatorCHAPTER ELEVEN: American Pharmaceutical Regulation in International Context: Audiences, Comparisons, and Dependencies; CHAPTER TWELVE: Conclusion: A Reputation in Relief; PRIMARY SOURCES AND ARCHIVAL COLLECTIONS; INDEX 330 $a The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to re 410 0$aPrinceton studies in American politics. 606 $aPharmaceutical policy$zUnited States 606 $aDrugs$xResearch$zUnited States 608 $aElectronic books. 615 0$aPharmaceutical policy 615 0$aDrugs$xResearch 676 $a362.17/82 700 $aCarpenter$b Daniel P.$f1967-$0878941 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910459384503321 996 $aReputation and power organizational image and pharmaceutical regulation at the FDA$91962629 997 $aUNINA